CKPT - Checkpoint Therapeutics - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

42.24M

Cash

4.846M

Avg Qtr Burn

-12.99M

Short % of Float

5.28%

Insider Ownership

16.69%

Institutional Own.

15.69%

Qtr Updated

03/31/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
CK-301 (Cosibelimab) (Anti-PD-L1 Antibody) Details Cutaneous squamous cell carcinoma, Cancer, Solid tumor/s	PDUFA Approval decision	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Olafertinib (CK-101) (EGFR Inhibitor) Details Non-small cell lung carcinoma, Cancer, Solid tumor/s	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CK-301 (Cosibelimab) (Anti-PD-L1 Antibody) Details Non-small cell lung carcinoma, Cancer, Solid tumor/s	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.